Informa Australia is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Healthcare | Technology

The start of a drug development revolution?

2 Aug 2019, by Amy Sarcevic

Professor Nikolai Petrovsky, a pioneer in the field of immuno-informatics from Flinders’ University, claims to have developed the world’s first AI-generated drug to have entered human trials; and is encouraging other drug researchers to also consider AI technology.

Using tools such as Artificial Neural Networks (ANN), Hidden Markov models, Random Forrest Walk and Genetic Algorithms,  Professor Petrovsky’s team tested whether AI could find a better drug for stimulating the innate immune system – specifically, toll like receptor 9 (TLR9) – than human experts have been able to design so far.

“We trained the AI by exposing it to examples of DNA sequences which had previously been shown to activate the receptor, together with examples of DNA sequences which don’t work. Through this repeated training the ANN ‘learned’ its own ways to identify DNA patterns that would potently stimulate TLR9”, said Petrovsky.

Using this approach, the AI identified completely new ligands of TLR9 for use as immune stimulating drugs and vaccine adjuvants.

“It took about six months for the AI to propose some suggested TLR9 active drugs it had designed. We got them synthesised and they proved to be extremely effective at activating TLR9.

“We then confirmed their safety and effectiveness in animal models. There wasn’t any toxicity; and from there we were able to move them rapidly into human clinical trials – as both vaccine adjuvants and as anti-cancer compounds”, he said.

When asked how the AI was able to  design TLR9 active drugs better than human experts, Petrovsky said, “This is the beauty of AI. While we know the theory of how it works in principle, we can’t tell afterwards exactly how it came up with the proposed solution.

“The technology has a ‘mind’ and ‘intelligence’ of its own. We give it the tools and the training and it then goes and figures the problem out for itself. It’s like a parent teaching a child how to read and that child goes onto to write a brilliant novel, something the parent themself had never conceived of when teaching the child.

“AI technology matures in the same way as a human. It acquires and accumulates knowledge and intelligence. It does the thinking, and looks for the complex patterns in the data  so that humans don’t have to, or may not even be capable of”, he added.

The entire process took the researchers just four years, to go from drug discovery to human trials, a far cry from the average ten to twenty years it normally takes to bring a drug from initial lab screening to human trials.

“Normally a laboratory scientist would screen millions of compounds to get a useful lead which can take decades. The AI does this far more efficiently and, without stating the obvious, without requiring a salary in the process. The time and cost savings are incredibly significant”, Petrvosky added.

As well as being a time- and capital-intensive process, much of the investment into drug discovery goes to waste, with only one out of every ten therapies that reach human Phase 1 going on to gain regulatory approval.

Petrovsky says AI technology can potentially improve these conversion rates – and returns on investment – for the drug industry. But he says there is a way to go before the industry fully embraces the technology.

The last few decades have seen a proliferation of health-related AI technologies, deployed in applications such as treatment design, digital consultation and medical management. However, AI’s use in drug discovery and basic science research has been much more hesitant.

“There’s been a significant amount of resistance and skepticism amongst basic science researchers”, said Petrovsky. “I’m not quite sure why this is, particularly when you consider the low conversion rates and returns on drug R&D investment that currently exist. Few would doubt that we need a better approach and I believe that AI can provide exactly that”.

Twenty five years ago when doing his PhD, Professor Petrovsky and his colleagues were one of the first teams in the world to apply AI tools in immunology research, with Professor Petrovsky personally coining the term “immuno-informatics”, a term now widely used to describe the field.

Presenting at the AI, Machine Learning and Robotics in Health conference – due to take place 24-25 October 2019 – Professor Petrovsky will share further details of his latest AI-related drug discovery research.

Learn more and register here.

Blog insights you may like

Get all the latest on Informa news and events

Informa Australia is the nation's leading event organiser. Our events comprise of large scale exhibitions, industry conferences and highly specialised corporate training.

Find out more

Subscribe to Insights
SUBSCRIBE 

Join Our Newsletter
Informa Insights

Stay up-to-date with all the latest
updates, upcoming events & more.
close-link